Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer.


Survival in patients with metastatic esophageal and gastric cancer is dismal. No standard treatment has been established. Carboplatin/paclitaxel is active in both advanced gastric and esophageal cancer. Here we retrospectively present our single center experience. Between 1998 and 2013, a total of 134 patients with metastatic esophageal and gastric… (More)
DOI: 10.1111/dote.12279


5 Figures and Tables


Citations per Year

Citation Velocity: 20

Averaging 20 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.